Boston, MA 05/23/2013 (wallstreetpr) – The share prices of Insmed Inc. (NASDAQ:INSM) surged by 9.80 percent to close at $12.44 per share for the last trading session. This was reported as a gain of $1.11 per share over the closing price of previous trading day. The company had traded in the range of $11.90 to $13.44, thereby readjusting the 52 week high price level of Insmed Inc. (NASDAQ:INSM) to $13.44 per share. The 52 week low price level of the company is $2.69 per share.
Insmed Inc. (NASDAQ:INSM) had managed to retain its outperform rating given by Wedbush research analysts through its efficiency and effectiveness of operations. In the recently posted quarterly results of Insmed Inc. (NASDAQ:INSM), the biopharmaceutical company reported earnings per share of ($0.43) which was observed to be less than the analysts’ estimate of ($0.46) earnings per share.
The biopharmaceutical company focuses on development and commercialization of targeted inhalation therapies for patients with lung diseases. Insmed Inc. (NASDAQ:INSM) has developed its leading product candidate, ARIKACE which is designed to deliver the anti infective drug directly to the infected area of the lungs. The product could be used treatment of two infections namely cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM).
Insmed Inc. (NASDAQ:INSM) holds a market capitalization of $391.71 million and the average trading volume for the company is 328,620 shares per day. The biopharmaceutical company had floated 31.49 million shares to the equity stock holders and holds an institutional ownership of 52 percent of its capital.
